Clinical Trial Update: LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye [Phase 3]

View source ↗

Summary

Phase III trial investigating intravitreal DE-109 Sirolimus for active non-infectious uveitis of the posterior segment; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-infectious Uveitis

Drugs mentioned

• DE-109 sirolimus (sirolimus)

Snippet

Sponsor: Santen Inc. | Conditions: Non Infectious Uveitis | Phase 3 | Status: TERMINATED | Results posted: 2023-12-04